FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair restated a market perform rating on shares of FibroGen in a research report on Monday, June 3rd.

FibroGen Trading Down 1.7 %

Shares of NASDAQ:FGEN opened at $0.40 on Friday. FibroGen has a 1-year low of $0.33 and a 1-year high of $2.93. The stock has a market capitalization of $39.73 million, a P/E ratio of -0.16 and a beta of 0.69. The business has a 50-day moving average price of $0.51 and a two-hundred day moving average price of $1.04.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million for the quarter, compared to the consensus estimate of $33.00 million. During the same period last year, the firm earned ($0.65) earnings per share. As a group, equities analysts predict that FibroGen will post -0.91 EPS for the current year.

Institutional Investors Weigh In On FibroGen

Large investors have recently bought and sold shares of the company. Alpine Global Management LLC acquired a new position in FibroGen in the first quarter valued at about $25,000. Delap Wealth Advisory LLC acquired a new position in shares of FibroGen in the 1st quarter valued at approximately $27,000. Acadian Asset Management LLC increased its stake in FibroGen by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after purchasing an additional 34,937 shares in the last quarter. Sei Investments Co. raised its holdings in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the period. Finally, Accel Wealth Management bought a new position in FibroGen in the first quarter valued at approximately $103,000. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.